XML 18 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock Appreciation Rights (Tables)
6 Months Ended
Oct. 31, 2013
SARS [Abstract]  
Stock Appreciation Rights Vesting Schedule [Table Text Block]
Number of Years the Grantee has remained
a Torotel director following the Date of Grant
Shares represented
by a SAR in which
a Grantee is Vested
Under one
%
At least one but less than two
33
%
At least two but less than three
67
%
Three or more
100
%
Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity [Table Text Block]
 
2013
2012
 
SARs
Under
Option
Weighted
Average
Grant
Price
SARs
Under
Option
Weighted
Average
Grant
Price
Outstanding at beginning of period
320,000

$
0.409

280,000

$
0.429

Granted
40,000

$
0.410

40,000

$
0.270

Exercised

$


$

Forfeited

$


$

Outstanding at end of period
360,000

$
0.409

320,000

$
0.409

SARs exercisable at end of period
280,000

$
0.415

243,000

$
0.417

Weighted average fair value of SARs granted during the period
 

$
0.410

 

$
0.270

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
 
2013
2012
Number outstanding
360,000

320,000

Range of grant prices, upper limit
$
0.695

$
0.695

Range of grant prices, lower limit
$
0.208

$
0.208

Weighted average grant price
$
0.409

$
0.417

Weighted average contractual life remaining (in years)
4.91

5.36

10-day average market price
$
1.200

$
0.281

Weighted average stock volatility
137.52
%
150.38
%
Weighted average expected life
4.42

4.72

Weighted average risk free rate
1.10
%
0.76
%
Weighted average dividend yield
%
%
Weighted average fair value price
$
1.143

$
0.260

Aggregate fair value
$
290,000

$
56,000

Aggregate intrinsic value
$
220,000

$
2,000

Total compensation expense for three months ended October 31
$
124,000

$
2,000

Total compensation expense for six months ended October 31
$
217,000

$
8,800

Unrecognized compensation expense related to non-vested SARs granted
$
68,000

$
15,000

Expected period to recognize compensation expense related to non-vested SARs granted (in years)
1.94

2.08

Total liability for SARs on consolidated balance sheets
$
313,000

$
61,000